14.0 References 
1. Balch CM, Soong SJ, Murad TM, et al. A multi-factorial analysis of 
melanoma. IV. Prognostic factors in 200 melanoma patients with distant 
metastasis (stage III). J Clin One 1:126-148, 1983. 
2. McClay EF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma. 
Semin Oncol 15:569-77, 1988. 
3. Luikart SD, Kennealey GT, Kirkwood JM. Randomized Phase III trial of 
vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine 
in malignant melanoma. J Clin Oncol 2:164-8, 1984. 
4. Ahmann DL, Creagan ET, Hahn RG, et al. Complete responses and long-term 
survivals after systemic chemotherapy for patients with advanced malignant 
melanoma. Cancer 63:224-7, 1989. 
5. DuPont G, Schuchter LM. Disseminated melanoma — Is there a new standard 
therapy? NE JM 327:560-61, 1992. 
6. Cocconi G, Bella M, Calabrasi F, et al. Treatment of metastatic melanoma 
with dacarbazine plus tamoxifen. NEJM 327:516-523, 1992. 
7. Oettgen HF, Livingston PO. Melanoma. In: Biologic Therapy of Cancer , eds . 
VT DeVita, S Heilman, SA Rosenberg. JB Lippincott, Philadelphia, 1991, 
Section 26.2, pp. 682-701. 
8. Weisenburger TH, Jones PC, Ahn SS, et al. Active specific intralymphatic 
immunotherapy in metastatic malignant melanoma: Evidence of clinical response. 
J Biol Response Mod 1:57, 1982. 
9. Cassel WA, Murray DR, Phillips HS. A Phase II study on the postsurgical 
management of stage II malignant melanoma with Newcastle disease virus 
oncolysate. Cancer 52:856, 1983. 
10. Harris JE, Hollinshead AC, Fuller B, et al. Active specific immunotherapy 
in malignant melanoma, ECOG pilot study PE-860 [abstract] . Proc Am Soc Clin 
Oncol 2:56, 1983. 
11. Calkins ER, Sondak VK, Nizze JA, et al . The effect of adjuvant tumor cell 
vaccine on antimelanoma antibody titers in stage II malignant melanoma 
patients [abstract]. Proc Am Soc Clin Oncol 3:259, 1984. 
12. Humphrey LJ, Taschler-Collins S, Goldfarb PM, et al . Adjuvant 
immunotherapy for melanoma. J Surg Oncol 25:203, 1984. 
13. Morton DL. Adjuvant therapy for malignant melanoma: Status of clinical 
trials at UCLA. Int J Immunother 2:31, 1986. 
14. Tallberg T, Kalima T, Halttunen P, et al. Postoperative active specific 
immunotherapy with supportive measures in patients suffering from recurrent 
metastasized melanoma: Case reports of six patients. J Surg Oncol 33:115, 
1986. 
15. Hersey P, Edwards A, Coates A, et al. Evidence that treatment with 
vaccinia melanoma cell lysates (VMCL) may improve survival of patients with 
stage II melanoma. Cancer Immunol Immunother 25:257, 1987. 
Recombinant DNA Research, Volume 18 
[ 360 ] 
